Announcements Trials
Browse Landscape

Phase

Phase 2 37Phase 1/2 14Phase 1 11Phase 3 5Phase NA 3Phase EARLY_PHASE1 2Phase 4 1

Status

Completed 164Active not recruiting 47Recruiting 45Unknown 35Terminated 27Withdrawn 5Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3Thoracic 2

Conditions

Multiple Myeloma 3Recurrence 2Neoplasms 2Vomiting 1Small Cell Lung Carcinoma 1Nausea 1Lung Neoplasms 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Dexamethasone × Clear all
NCT06232707 2024-05-31

ALUMMINATE

Celgene

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT04288765 2021-07-09

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Grupo Cooperativo de Hemopatías Malignas

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma

NCT03334487 2018-12-26

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

AbbVie

Phase 3 Withdrawn
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT00891761 2015-04-17

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

GlaxoSmithKline

Phase 3 Withdrawn
Thoracic

Lung Neoplasms, Nausea, Neoplasms, Vomiting

NCT01266811 2013-01-28

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Centocor, Inc.

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡